Insider Monkey
Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves
📈
AI Sentiment
Highly Positive
9/10
- Home
- PTCT
as of 01-27-2026 3:41pm EST
$75.18
$1.06
-1.38%
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 6.1B | IPO Year: | 2013 |
| Target Price: | $73.76 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.95 - $87.50 | Next Earning Date: | 02-26-2026 |
| Revenue: | $1,779,150,000 | Revenue Growth: | 97.54% |
| Revenue Growth (this year): | 129.8% | Revenue Growth (next year): | -47.25% |
AI-Powered PTCT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.38%
76.38%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of PTC Therapeutics Inc. (PTCT)
Pauwels Eric
Sell
CHIEF BUSINESS OFFICER
PTCT Jan 12, 2026
Avg Cost/Share
$78.70
Shares
1,024
Total Value
$80,588.80
Owned After
80,141
SEC Form 4
Pauwels Eric
Sell
CHIEF BUSINESS OFFICER
PTCT Jan 9, 2026
Avg Cost/Share
$77.41
Shares
1,722
Total Value
$133,300.02
Owned After
80,141
SEC Form 4
Boulding Mark Elliott
Sell
EXEC. VP AND CLO
PTCT Jan 9, 2026
Avg Cost/Share
$78.56
Shares
2,314
Total Value
$180,320.36
Owned After
111,312
Klein Matthew B.
Sell
CHIEF EXECUTIVE OFFICER
PTCT Jan 8, 2026
Avg Cost/Share
$76.45
Shares
2,514
Total Value
$192,195.30
Owned After
394,453
SEC Form 4
Utter Christine Marie
Sell
SVP, CHIEF ACCOUNTING OFFICER
PTCT Jan 8, 2026
Avg Cost/Share
$76.45
Shares
1,034
Total Value
$79,049.30
Owned After
72,693
SEC Form 4
Pauwels Eric
Sell
CHIEF BUSINESS OFFICER
PTCT Jan 8, 2026
Avg Cost/Share
$76.62
Shares
4,602
Total Value
$352,057.18
Owned After
80,141
Almstead Neil Gregory
Sell
CHIEF TECHNICAL OPS OFFICER
PTCT Jan 8, 2026
Avg Cost/Share
$76.45
Shares
940
Total Value
$71,863.00
Owned After
115,196
Boulding Mark Elliott
Sell
EXEC. VP AND CLO
PTCT Jan 8, 2026
Avg Cost/Share
$76.69
Shares
4,033
Total Value
$308,760.17
Owned After
111,312
Golden Lee Scott
Sell
EVP & CHIEF MEDICAL OFFICER
PTCT Jan 8, 2026
Avg Cost/Share
$76.45
Shares
866
Total Value
$66,205.70
Owned After
92,428
SEC Form 4
Klein Matthew B.
Sell
CHIEF EXECUTIVE OFFICER
PTCT Jan 7, 2026
Avg Cost/Share
$77.48
Shares
3,016
Total Value
$233,679.68
Owned After
394,453
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Pauwels Eric | PTCT | CHIEF BUSINESS OFFICER | Jan 12, 2026 | Sell | $78.70 | 1,024 | $80,588.80 | 80,141 | |
| Pauwels Eric | PTCT | CHIEF BUSINESS OFFICER | Jan 9, 2026 | Sell | $77.41 | 1,722 | $133,300.02 | 80,141 | |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Jan 9, 2026 | Sell | $78.56 | 2,314 | $180,320.36 | 111,312 | |
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Jan 8, 2026 | Sell | $76.45 | 2,514 | $192,195.30 | 394,453 | |
| Utter Christine Marie | PTCT | SVP, CHIEF ACCOUNTING OFFICER | Jan 8, 2026 | Sell | $76.45 | 1,034 | $79,049.30 | 72,693 | |
| Pauwels Eric | PTCT | CHIEF BUSINESS OFFICER | Jan 8, 2026 | Sell | $76.62 | 4,602 | $352,057.18 | 80,141 | |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Jan 8, 2026 | Sell | $76.45 | 940 | $71,863.00 | 115,196 | |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Jan 8, 2026 | Sell | $76.69 | 4,033 | $308,760.17 | 111,312 | |
| Golden Lee Scott | PTCT | EVP & CHIEF MEDICAL OFFICER | Jan 8, 2026 | Sell | $76.45 | 866 | $66,205.70 | 92,428 | |
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Jan 7, 2026 | Sell | $77.48 | 3,016 | $233,679.68 | 394,453 |
Latest PTC Therapeutics Inc. News
PTCT Breaking Stock News: Dive into PTCT Ticker-Specific Updates for Smart Investing
Compare PTCT vs Leading Stocks
See how PTCT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PTCT PTC Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.